# Phrontline Biopharma funding rounds and investors

As of 19 Nov 2026, Phrontline Biopharma has raised $100M across 2 verified rounds on record; latest: $40 million Series A led by Decheng Capital and Oriza Seed Venture Capital, announced 13 Nov 2026.

Phrontline Biopharma develops innovative antibody-drug conjugates (ADCs) focused on oncology therapies.

Website: https://www.phrontlinebio.com/  
Headquarters: Hangzhou, China  
Page: https://fireround.dev/companies/phrontline-biopharma

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-11-13 | Series A | $40 million | Decheng Capital, Oriza Seed Venture Capital | C&D Emerging Investment, Jifeng Ventures, Lapam Capital, Medfine Health Fund, SongQing Capital | [phrontlinebio.com](https://phrontlinebio.com/m/News/149.html), [phrontlinebio.com](https://www.phrontlinebio.com/News/149.html), [phrontlinebio.com](https://phrontlinebio.com/m/News.html) |
| 2025-11-25 | Pre-A | $60 million | Lapam Capital | C&D Emerging Investment, Decheng Capital, Guofang Innovation, HanKang Capital, Jifeng Ventures, Medfine Health Fund, Samsung Ventures, Sino Biopharmaceutical, SongQing Capital | [phrontlinebio.com](https://www.phrontlinebio.com/m/News/89.html), [prnewswire.com](https://www.prnewswire.com/news-releases/phrontline-biopharma-raises-60-million-in-pre-a-financing-to-advance-global-development-of-bispecific-and-dual-payload-adcs-302625090.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.
